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The introduction of allogeneic T lymphocytes into an immunoincompetent
host is known to lead to a potentially lethal disease, the graft-vs.-host disease
(GVHD),' which is associated with lesions ofvarious organs or tissues; in partic-
ular, in the acute phase of the disease, the intestinal tract and the epidermis (1-
3) are affected. The mortality and tissue damage are clearly dependent upon the
introduction ofallogeneic Tlymphocytes, but the proximal mechanisms oflesion
formation have not been clarified. They might involve, for the acute GVHD,
direct reactions between donor T lymphocytes and host target cells, or more
indirect mechanisms mediated by interleukins released by the donor T cells (4,
5), thereby stimulating a variety of cells capable of inflicting tissue damage such
as macrophages or large granular leukocytes (LGL) (6). There is experimental
evidence that the chronic form of GVHD, which is characterized by different
types of lesions, results from pathogenic mechanisms different from those in-
volved in acute GVHD (7).
Tumor necrosis/cachectin (TNF-a), a protein produced mainly by macro-
phages, has a wide variety ofactions in vivo and in vitro on many cell types other
than malignant ones, and appears to be a major mediator in inflammatory
processes (for review, see 8 and 9). The cutaneous and intestinal lesions charac-
teristic ofthe acute phase of GVHD show, in addition to lymphocytic infiltration
and epithelial alterations, isolated cell necrosis, epidermal cell necrosis in the
cutaneous lesions (10), and necrosis ofindividual epithelial cells in the intestinal
crypts (11). We therefore explored the possibility that TNF-a may play a role in
the etiology of these lesions by treating mice undergoing acute GVHD with
rabbit antibody against recombinant mouse TNF-a. This treatment almost
entirely prevented the cutaneous and intestinal lesions of the acute-phase of
GVHD, and markedly reduced overall mortality.
Materials and Methods
Mice.
￿
C57BL/10 (B10) and CBA/ca mice were purchased from Olac Ltd, Bicester,
United Kingdom, and were bred for two to three generations in our animal facilities.
This work was supported by grant 3.614.84 from the Swiss National Science Foundation.
'Abbreviations used in this paper.
￿
BMC, bone marrow cells; GVHD, graft-vs.-host disease; LGL,
largegranular lymphocytes; LN, lymph node.
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FIGURE 1 .
￿
Mortality curve of lethally irradi-
ated (B10 X CBA)F1 mice injected with B10
anti-Thy-I-treated bone marrow cells (con-
trols) supplemented or not with 2 X 106 B10
LN cells, and treated after 1 wk with 2 mg of
anti-TNF or normal rabbit IgG weekly until
day 35.
C57BL/6 (B6) H-2k mice were purchased from the Memorial Sloan-Kettering Cancer
Center, New York.
Induction of GVHD.
￿
Recipient mice >3 mo old, were irradiated by a Cesium source
(800 rad, delivered during 2-3 min) and injected intravenously with T depleted bone
marrow cells (BMC), either supplemented with T lymphocytes prepared from lymph
nodes (LN),or alone, as a control, according to a procedure described previously (4).
Anti-rTNF-a Antibody. IgG fraction was prepared by affinity chromatography on
protein A-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) from the serum of a
rabbit hyperimmunized with purified rTNF-a (12). The antibody activity of this IgG
fraction was detected by immunodiffusion in agar against the immunizing antigen, and
was quantitated in a TNF assay (13): a solution of 5 mg/ml neutralized the activity of 58
ng rTNF-a up to a dilution of 1 :81,000. The antibody effect of this IgG fraction was also
determined in vivo: a single intravenous or intraperitoneal injection of 2 mg completely
prevented the cutaneous necrosis induced by a 7-d hypodermic perfusion of a solution of
mouse TNF-a delivered by an osmotic minipump (Alza, Palo Alto, CA) (4 Jg/d). Normal
rabbit IgG, used as a control, was prepared by protein-Sepharose adsorption from the
serum of nonimmunized rabbits.
Histology.
￿
Specimens were fixed in 2% formaldehyde/80% ethanol, embedded with
paraffin or methyl metacrylate, and 5- and 1-pm sections were stained with hematoxylin
and eosin. For electron microscopy, specimens were fixed in 2.5% glutaraldehyde in
cacodylate buffer, 0.1 M pH 7.4; ultrathin sections were stained with uranyl acetate and
lead citrate, and examined with an electron microscope (Philips 400; Zurich, Switzerland).
Results
Effect of Anti-TNF Treatment on GVHD-induced Mortality and Weight Loss.
Lethally irradiated (B10 X CBA)FI mice were injected with T-depleted BIO
BMC and, unless mentioned otherwise, 2 X 106 B10 LN cells as a source of
parental T cells. Injection of this number of parental T cells leads to a GVHD
that becomes clinically apparent (weight loss, hair ruffling) in about 2 wk, and is
followed by a mortality of -60% within 40 d, and >90% at 80 d (Fig. 1) . To
explore the possible effect of TNF on the course of this syndrome, mice were
injected after 1 wk, i.e., before the beginning of the clinical symptoms, with 2
mg of rabbit anti-TNF IgG, or 2 mg of normal rabbit IgG as a control. This
amount of anti-TNF was chosen because, in vivo, it entirely suppresses the effect
of local administration of TNF (see Materials and Methods). After this first
injection, mice were reinjected weekly with the same amounts of IgG until day1282
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35; anti-TNF activity was detectable in the serum of treated mice until day 35
with titers ranging between 1:30-1:200. Anti-TNF treatment resulted in a
decrease in mortality, with a survival rate of ^-70% at days 40 and 80; normal
rabbit IgG treatment had no effect on the course ofthe disease (Fig. 1). On day
18, normal rabbit IgG-injected GVHD mice showed a weight loss of 11% (±4%,
mean ± SD) compared with control mice without GVHD (i.e., not injected with
parental T cells), while there was no significant difference in weight between
anti-TNF-injected GVHD mice and control mice. Somewhat comparable results
of the anti-TNF treatment on mortality and weight loss were observed with a
similar protocol in another strain combination involving only minor histocom-
patibility antigens (C57BL/6H-2kcells injected into CBA mice) (data not shown).
In spite ofthis effect ofanti-TNF treatment, at no time during the course of
the untreated GVHD was any TNF activity detectable in the serum. This is in
contrast to what we have observed in mice with an acute malaria infection and
neurologic symptoms, i.e., cerebral malaria, also prevented by anti-TNF treat-
ment (14). On the basis ofthe course ofthe disease and the effects ofanti-TNF
treatment, the period of the 16-18th days was selected for histologic study of
the skin and bowel.
Passive Immunization with Anti-TNF IgG Prevents the Cutaneous Lesions of the
GVHD. The skin lesions observed in normal rabbit IgG treated hostsat the 16-
18th day of the GVHD were similar to those previously reported in various
donor-host combinations (15), and were characterized by: (a) an increase in the
number of epidermal cell necroses (ECN); (b) foci of lichenoid hyperplastic
reactions (LIZ); (c) areas ofepidermal atrophy; (d) loss of the hypodermic fat. As
shown in Fig. 2, these lesions, which are widespread enough to be all detected
within a small skin area, were markedly decreased in anti-TNF-treated mice .
Quantification of the various components ofthese lesions in the three groups of
mice is shown in Table 1. As can be seen by comparing Fig. 2, c and d, the anti-
TNF treatment also markedly decreased lymphoid cell infiltration in the epider-
mis.
Passive Immunization with Anti-TNF IgG Prevents the Intestinal Lesions of
GVHD. Mice with GVHD that were injected with normal rabbit IgG had severe
intestinal lesions consisting of a dilatation and hypertrophy of the small bowel,
marked flattening of the villi and elevation of the crypts, with an increased
number of mitoses and frequent necroses of single cells within the crypt epithe-
lium (Fig. 3, b and d). By electron microscopy, the single altered epithelial cells
were characterized by condensation ofthe nuclear chromatin(Fig. 3e) or marked
compaction ofthe whole cell (Fig. 3f), i.e., changes characteristic of the form of
cell death called apoptosis (16, 17). In contrast to what has been observed in
other models ofintestinal GVHD studied at an earlier stage (days 5-6) (5), there
was no marked infiltration of intraepithelial lymphocytes within the crypts;
however, increased numbers of lymphoid cells, and occasionally neutrophils were
present in the lamina propria. Electron microscopy showed that the endothelium
ofsmall venules was usually swollen. All these lesions were almost absent in the
anti-TNF-treated mice (Fig. 2, a and c); the quantification of these changes is
shown in Table I. Anti-TNF treatment also suppressed the increased expressionPIGUET ET AL .
FIGURE 2 .
￿
Skin of mice on the 18th day of GVHD . Abdominal skin of mice treated with
anti-TNF (A and C) or with normal rabbit IgG (B andD) . At low magnification (original X 8),
the anti-TNF-treated mouse (A) has a skin similar to that of control irradiated mice not
injected withTlymphocytes (not shown), with a regular epidermisandpresence ofhypodermic
fat (arrow); the control IgGtreated mouse (B) shows foci ofepidermalatrophy (arrowhead) and
lichenoid regeneration (thin arrows); the hypodermic fat is absent . At higher magnification
(original X 400), the epidermis of the anti-TNF-treated mouse (C) has two to three cell layers
with little or no cellular infiltration ; in contrast, the epidermis of a control IgG-treated mouse
(D) shows an area of lichenoid reaction with increment of the epidermal thickness, cellular
infiltration (arrowhead) and necrosis of isolated epidermal cells (thin arrows).
TABLE I
Passive Immunization with Anti-TNF IgG Prevents the Cutaneous and Intestinal Lesions of
the Acute Phase ofthe GVHR
Skin lesions
￿
Intestinal lesions
Results are means t SD ofthe values observed in six to nine individual mice in eachgroupon the 16-18th day .
* Number ofnecrotic epidermal cells (ECN) by microscopic field (X 102). Difference between group b and c : P < 0.05 .
$ Number of foci ofepidermal atrophyand lichenoid reaction (LR) perarea of2-cm histologic sections.
Number ofmice with detectable hypodermic fat per number ofmice examined .
l Difference between group band c : P < 0.05 .
Measured with a calibrated ocular. X 400. P < 0 .01 and <0 .1 .
** Number ofcrypt cell mitoses per microscopic field on thin sections (1 u) examined at x 1,000 (p < 0 .05).
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of la on the gut epithelial cells observed in the GVHD lesions (data not shown)
(5, 18) .
Effect ofAnti-TNF Treatment on the Spleen.
￿
On day 18, the spleens ofGVHD
mice were smaller than those of controls, with a recovery of 2.3 and 3.6 X 107
cells for normal rabbit IgG- and anti-TNF-treated GVHD, respectively, com-
pared with 8.6 X 107 for control mice . The spleens of both anti-TNF- and
normal IgG-treated mice showed structural disorganization, with growth of all
Group Cell injected Treatment
ECN* Atrophy phy and
LR=
Hypo-
dermic
fat#
Duodenal
circum-
ferencel
mm
Length
of
villi2
mm x 10-2
Length
of
crypts'
mm X 10-2
Mitoses**
a BMC, anti-Thy-1 - 10 .8 ± 8 0 5/6 6 .8 ± 1 .0 38 ± 8 10 ± 8 0.73 ± 0 .2
b BMC, anti-Thy-1 nIgG 64 t 37 1 .3 t 1 .0 1/9 11 .6 t 2 .1 15 t 9 29 :t 18 1 .6 t 0.3**
+ LN cells
c BMC, anti-Thy-1 Anti-TNF 23 t 17 0 .1 t 0 .1 9/9 8 .4 t 1 .2 44 t 8 10 t 3 0.60 t 0 .4
+ LN cells1284
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Anti-TNF IgG Does NotPrevent Foreign T Cell Proliferation in
theHost Spleen
PIGUET ET AL.
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Discussion
Results arethe mean ± SD ofthe values of spleen cells ['H]TdR incorpo-
ration observed in five (1310 x CBA)F, host mice in each group, killed 5
d afterlethal irradiation and transfer of 106 syngeneic or B10 LN cells. 5
X 106 spleen cellswere cultured for 4 h in the presence of [9H]TdR, and
the culture was then processedforscintillation counting (4).
hematopoietic lineages without any significant difference between the two
groups.
Anti-TNF Treatment Does Not Inhibit the Proliferative Response of the Donor T
Lymphocytes. To determine whether anti-TNF treatment interferes with the
proliferation of donor T lymphocytes, irradiated F, mice were injected with
syngeneic or parental LN cells, and treated, without bone marrow reconstitution,
with anti-TNF or normal rabbit IgG. 5 d later, the number of cells recovered
from the spleen and their proliferative activity were comparable in both groups
of GVHD mice, indicating that anti-TNF treatment does not interfere with the
proliferation ofparental grafted T cells (Table II).
The present results show the TNF plays an essential role in the pathogenesis
of the cutaneous and intestinal lesions of the acute phase of the GVHD . These
lesions affect primarily the epithelial cells oftheepidermisandofthe gut mucosa,
and usually appear during the second and third week after transplantation in
man; in the mouse model used, the number of T lymphocytes added to the
transplanted parental bone marrow cells was chosen to give a disease of compa-
rable chronology and severity. The skin and gut lesions observed during the
third week of GVHD were almost totally prevented by passive immunization
with rabbit anti-TNF IgG; mortality during the following weeks was also mark-
FIGURE 3.
￿
Duodenum of mice on the 18th day of GVHD. Duodenum of mice treated with
anti-TNF (A and C) or with normal rabbit IgG (B and D). At low magnification (original x 6)
the anti-TNF-treated mouse (A) has a duodenum comparable to that of controls irradiated
not injected with T lymphocytes (not shown); the control IgG-treated mouse (B) shows a
dilatation of the duodenum, with a marked flattening of villi and elevation of the crypts. At
higher magnification (original x 400), a crypt of the anti-TNF-treated mouse (C) is normal
andcontains unalteredPaneth cells (arrow); thereis little lymphoid infiltration of theepithelium
or the submucosa. In contrast, a damaged cryptof acontrol IgG treated mouseshows mitosis
(arrow) and isolated cell necrosis (arrowhead); lymphocytes are not numerous within the
epithelium but there is amarked lymphoid infiltration of the submucosa. E and F: ultrastruc-
turalappearance of epithelial cell necrosis in thecrypts ofcontrol IgGtreated mice. E: pycnotic
nucleuswith normal cytoplasm (original magnification X 6,000); F: compaction of whole cell
(original magnification x 1,200).
Spleen
LN cells injected
(strain) Treatment Cell [3H]TdR
recovery incorporated
x 10-5 cpm x 10-3
(CBA x B10)F, None 6 ± 2 9 t 5
1310 nIgG 25 t 4 598 t 107
1310 Anti-TNF 30 ± 9 515 t 1271286
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edly reduced. In contrast, lesions of chronic GVHD that appear to have a
different pathogenesis (7) were not modified; hepatic lesions were found in both
groups after the fourth week ofthe disease (data not shown).
Two questions are addressed: what is the source of TNF during the acute
phase of GVHD, and what is its possible mode ofaction? At no time during the
course of the disease was TNF activity detectable in the blood, in contrast to
what has been observed in mice with endotoxin shock (19) and with cerebral
malaria (acute malaria complicated by neurologic symptoms) (14), two conditions
that can also be prevented by anti-TNF treatment (14, 19). In the latter case,
however, there isa marked accumulation ofmacrophages in thelymphoid organs
(and in the brain vessels) (14), which is not observed in acute GVHD. The source
of TNF in GVHD must therefore be local, in relation to the cellular infiltration
of the skin and ofthe gut mucosa elicited by the response ofdonor lymphocytes
to the host antigens. For the gut, the mechanisms initiating Tcell infiltration of
the whole intestinal mucosa have been established (5). The stimulated T cells
release, among other lymphokines, IFN--y (5), which is probably responsible for
the increased la expression observed on the mucosal epithelia (5, 18), and may
also result in an increased production of TNF-a by the local macrophages (19).
TNF-a may also be released by the stimulated T lymphocytes themselves; TNF-
a mRNA has indeed been detected in the gut intraepithelial T lymphocytes
isolated from mouse GVHD (D. Guy-Grand, P. F. Piguet, and P. Vassalli,
manuscript in preparation). Finally, another source ofTNF-a may be the LGL,
a cell variety that releases TNF-a upon stimulation (20), and which has been
found in the skin lesions of mice with acute GVHD, where it is suspected to be
responsible for the epidermal cell necrosis (6); proliferation of LGL may be
induced by IL-2 released by stimulated, grafted T cells. Thus, there may be
several local sources of TNF-a in the epidermal and intestinal lesions of acute
GVHD. It is also possible that the rabbit anti-TNF-a antibodies recognize some
crossreactive antigenic determinant on a product of activated lymphocytes that
is structurally and functionally related to TNF-a, e.g., lymphotoxin or TNF-0
(21), and that the effects observed in the present experiments are in part due to
blockage of TNF-f3. TNF-,Q has the same wide range ofbiologic activities as does
TNF-a (7, 8). It should be noted, however, that rabbit anti-human TNF-a and
-,Q antisera show no crossreactivity (22).
Besides its capacity to induce the necrosis of some types oftumor cells, TNF-
a has a variety ofeffects on many cell types (8, 9), including necrosis ofnormal
cells when injected in vivo in large amounts (23). It acts on cells involved in
inflammation, in particular on endothelial cells, polymorphonuclear leukocytes,
and monocytes; in vitro, it leads to an increased adhesion of leukocytes to
endothelial cell monolayers (24, 25), probably due to the increased expression,
on endothelial cell membranes, of molecules associated with leukocyte and
lymphocyte adhesion (26). It is thus likely that a local release of this mediator
will lead to a self-aggravating chain of events, increasing the local concentration
of inflammatory cells; this probably explains why the cell infiltration of the skin
and gut lamina propria is so markedly decreased by anti-TNF treatment, while
this treatment does not alter the stimulation of division of the foreign T
lymphocytes by the host (Table II). The characteristic alterations of the acutePIGUET ET AL.
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GVHD in the skin and the gut, however, are those of the epithelial cells. They
consist of both isolated necrosis (within the rete ridge of the epidermis, and, in
the gut, in the bottom of the crypts) and acceleration of epithelial renewal,
manifested in the skin by the lichenoid hyperplastic reactions in the skin and in
the gut by crypt hyperplasia with an increased number of mitoses. Because these
alterations are so strikingly prevented by anti-TNF treatment, it appears that
TNF acts on the less differentiated cells of the epithelium (i.e, the stem cells) in
such a way as to induce their occasional death by apoptosis (16, 17) (as is also the
case for malignant cells sensitive to TNF [17]) and their stimulation to divide.
The hyperplasia might be a reparative process triggered by cell damage or death.
However, TNF has also been shown to increase the responsiveness of cells to
epidermal growth factor (EGF) (9); such an effect may therefore play a role in
the intestinal lesions and in the lichenoid reactions in the skin, since it is known
that epidermal growth factor accelerates in vivo skin (27) and gut epithelial
renewal (28). Finally, in the skin, the striking disappearance of the hypodermic
fat that accompanies the epidermal lesions is compatible with a local cachectin
effect, related to the inhibitory action of TNF on the adipocyte lipoprotein lipase
(8).
In conclusion, these experiments show that neutralization of TNF prevents
the development of the cutaneous and intestinal lesions characteristic of the
acute phase of GVHD. The favored interpretation is that the presence of
activated lymphocytes within the skin and the gut mucosa results in an increment
in the local production of TNF, which induces epithelial cell alterations and
necroses, as well as an increase of the inflammatory reactions within these
mucosae .
Summary
Lethally irradiated mice were injected with semiallogeneic, T-depleted bone
marrow cells and an amount of peripheral T lymphocytes sufficient to induce
graft-vs.-host disease (GVHD) becoming apparent on the second week after the
graft and leading to an increasing mortality rate within the following weeks
(>90% mortality within 80 d) . Mice receiving bone marrow cells alone had no
GVHD and were used as controls. Beginning on day 8, mice with GVHD were
injected weekly with 2 mg of either rabbit anti-mouse recombinant tumor
necrosis factor/cachectin (TNF-a) IgG, or normal rabbit IgG . On the 16-18th
d, mice were killed to examine the skin and intestinal lesions of the acute phase
of GVHD. The anti-TNF treatment resulted in an almost complete prevention
of the severe lesions seen in the mice treated with normal rabbit IgG, i.e., the
skin epidermal cell necrosis, foci of lichenoid hyperplastic reactions, and loss of
the hypodermic fat; in the gut dilatation with marked flattening of the villi and
elevation of the crypts, with increased numbers of mitoses and isolated crypt cell
necrosis. In addition to preventing these acute lesions, anti-TNF treatment
resulted in a significantly decreased mortality (^-70% survival at 80 d). These
results suggest that during acute GVHD, the activation of grafted lymphocytes
leads to a local release of TNF in the cutaneous and intestinal mucosae, which
induces epithelial cell alterations and increases the inflammatory reaction.1288
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